The National Institute for Health and Care Excellence (NICE) has launched the Preliminary Independent Model Advice (PRIMA) service to ‘health-check’ economic models. PRIMA is a fee-based consultancy service offering a detailed peer review service to help developers of drugs, medical devices and diagnostics, and public health interventions ensure the quality of their model structure, coding, usability and transparency.
The use of mesh implants to treat vaginal wall prolapse has been discussed in the Scottish Parliament. The debate centred around allegations that the review on mesh implants was flawed and the role of the Medicines and Healthcare Regulations Agency. The PROSPECT trial was mentioned in the course of the discussions. It has been announced that Professor Alison Brittle will lead a review into the process of the previous review and make recommendations for the conduct of similar reviews in the future. The recommendations that the procedure should not be offered routinely remain in place ahead of the NICE recommendations due to be published on 20 December 2017.
An article in the BMJ reports that the National Institute for Health and Care Excellence will announce that transvaginal mesh should not be used to treat vaginal wall prolapse. The guidance from NICE’s Interventional Procedure Advisory Committee, due to be published on 20 December, concluded that transvaginal mesh repair of anterior or posterior vaginal wall prolapse should be used only in the context of research. NICE said that its guidance had not yet been officially released and was subject to change. An independent review of the safety of transvaginal mesh procedures in Scotland, published in March 2017, concluded that they must not be offered routinely.
The latest National Institute for Health and Care Excellence (NICE) newsletter has been published. The newsletter has features on effective use of antibiotics, breast cancer drugs, guidance that people with inherited cholesterol disorder familial hypercholesterolaemia should be checked as early as possible, and an announcement that NICE will build in advice on when an intervention shouldn’t be offered to certain people because either the practice is unsafe, or there is strong evidence the practice is ineffective in terms of quality and/or cost compared with alternatives.
The Centre for Health Economics at the University of York have issued their latest newsletter. The newsletter has features on their research on global health economics, the influence of patient choice on non-attendance for out-patient appointments, the cost-effectiveness of diagnostic tests for prostate cancer, recommendations to NICE in relation to methods for the evaluation of cancer treatments and the impact of payment for dental x-rays on the volume of x-rays undertaken. Recent publications, conference activities and new projects are also listed.
The NICE guideline on glaucoma has been updated. In the latest version new recommendations have been added for case-finding, diagnosis, reassessment and treatment. Publications involving HERU staff are referenced in the guideline.
The October newsletter of the National Institute for Health and Care Excellence (NICE) has been published. Amongst the content there is a feature on antibiotic resistance in urinary tract infections and a blog post from the Programme Director of Scientific Affairs at NICE on why NICE are encouraging research into the impact of air pollution.